Alvotech Willing And Able To Go Stride For Stride On Pembrolizumab Manufacturing

Potential Regulatory Hurdle Not Concern For Now For Icelandic Firm

Alvotech stepped into its 2023 annual financing results call bursting with positive news and momentum, on the back of obtaining USFDA approval for its biosimilar Humira product and a bullish outlook for its strong pipeline of biosimilar candidates.

Pembrolizumab molecule
• Source: Shutterstock

Alvotech has indicated that it has little concern for now considering Merck & Co’s plan to shift manufacturing for its $25bn Keytruda (pembrolizumab) immuno-oncology juggernaut from batch to continuous perfusion, owing to the Icelandic firm’s previous investments in its own manufacturing.

As Alvotech presented its fourth-quarter and annual financial results, one analyst asked during the firm’s earnings call whether Merck’s move “could result in any regulatory delays to biosimilar launch in light of their recent

More from Biosimilars

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By 

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By 

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By 

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

More from Products